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Abstract: This article describes LifeTrain — the European common framework for continuing professional develop-
ment in the biomedical sciences. An important goal of LifeTrain is to support biomedical professionals to work colla-
boratively across disciplines, sectors and national boundaries. LifeTrain is an open community with a unifying goal; it 
brings together many excellent, but disparate, activities into a process towards establishing a focused and coherent 
framework for continuing professional development in the biomedical sciences. This collaborative approach provides 
the critical mass to make a major contribution to strengthen the skills and competencies of biomedical professionals in a 
rapidly changing environment. LifeTrain's signatories, which include multinational pharmaceutical companies, research 
infrastructures, professional and scientific bodies, higher-education institutes and research institutes, have agreed to the 
principles of the framework and to continue to collaborate to implement LifeTrain. We warmly invite others to join us. 
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1. Introduction 
any factors contribute to successful research, 
and well-trained professionals, who are 
committed to staying at the leading edge of 
developments in their field, are the underlying foun-
dation. Europe is taking leadership to retain global 
competitiveness in medicines research and develop-
ment by building the right environment for innovative 
education and training. This environment needs to 
address several challenges. Firstly, the lack of mobility  
across national borders is a major hurdle to Europe’s 
competitiveness: highly qualified professionals may 
have to undergo retraining to enable them to advance 
their careers outside of the country or sector in which 
they received their initial training. Secondly, there is a 
perceived gap between the competencies that gra-
duates come out of university with and the competen-
cies that employers look for[1,2]. Thirdly, established 
mechanisms for maintaining professional competency 
are being challenged by rapid changes in science and 
technology — especially the increasingly rapid de- 
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velopment of disruptive technologies (new technolo-
gies that unexpectedly displace established ones; 
next-generation sequencing is a good example)[3], the 
cross-disciplinary, team-working nature of modern 
science and the need for greater communication and 
collaboration across and beyond traditional boundaries. 
In medicines research, development, processing, deli-
very and usage there is a huge variation in the types of 
scientists required, yet traditional scientific training 
tends neither to recognise, nor to cater for, these dif-
ferences.  
The Innovative Medicines Initiative (IMI)[4] and 
Europe’s emerging biological and medical research 
infrastructures[5] were established to help Europe stre-
ngthen its position in research and development 
(R&D). IMI is Europe’s largest public–private part-
nership; it is a joint undertaking between the European 
Commission and the European Federation of Pharma-
ceutical Industries and Associations (EFPIA)[6]. Thr-
ough a series of innovative education and training 
programmes[7], IMI aims to address the current lack of 
holistic, integrative and translational approaches in 
education and training, and is therefore a unique part 
of a broader effort to strengthen Europe’s competi-
tiveness in medicines R&D in the face of increased 
global competition. 
The Biological and Medical Sciences Research In-
frastructures (BMS RIs)[8] on the ESFRI Roadmap are 
pan-European facilities, resources and related services 
used by the scientific community, which provide an 
interdisciplinary, innovative environment where world- 
leading scientists conduct world class research and 
employ cutting-edge technologies based on open 
access across all BMS RIs. Implementation of the 
BMS RIs acts as a driving force across more than one 
thousand European research institutions and two mil-
lion researchers[8]. Research Infrastructures have been 
recognized as key foundations for building a truly ef-
fective European Research Area[9] and their imple-
mentation is one of the priorities of the Innovation 
Union[10]. As well as providing pan-European open 
access to cutting-edge technology platforms for aca-
demia and industry, and promoting interdisciplinary 
research in biological and medical sciences across 
Europe, they have an explicit mission to provide 
training and education to future professionals in the 
life sciences.  
Over the past five years, the IMI Education and 
Training projects, coordinated by the EMTRAIN 
project, have consulted broadly to develop LifeTrain 
— the European Common Framework for Continuing 
Professional Development[11]. An important goal of 
LifeTrain is to address the issues summarised above 
by supporting medical, biomedical and pharmaceutical 
professionals to work collaboratively across discip-
lines and national boundaries more readily. Our dis-
cussions have involved representatives from European 
professional/scientific bodies; the ESFRI BMS RIs; 
the European Association for Bio-Industries (Europa-
Bio); major employers in pharmaceutical R&D (the 
EFPIA companies), national regulatory agencies, the 
European Medicines Agency (EMA), small and me-
dium-sized enterprises (SMEs) and major contract 
research organisations (CROs); the European Univer-
sity Association (EUA); the European Science Foun-
dation (ESF); the Organisation for PhD Education in 
Biomedicine and Health Sciences in the European 
System (Orpheus) and many private course providers. 
2. LifeTrain Framework 
The LifeTrain framework consists of a series of key 
messages (Box 1) and four sets of agreed principles 
(Box 2), one each for professional/scientific bodies, 
course providers, employers, and individual professio-
nals. Here, we present the current version of the fra-
mework and provide some background to explain why 
it has gained broad support. On the website[12], we list 
the organisations and individuals that have worked 
with us to shape the framework, flagging those insti-
tutions that have formally signed up to the agreed 
principles of the framework and are committed to 
working towards the implementation of LifeTrain. The 
framework continues to evolve as we engage with a 
broader community, and we warmly invite those who 
have not yet participated in this initiative to do so. 
2.1 Key Messages 
Through a series of workshops (2011, 2012, 2013 and 
2015) and extensive consultation between workshops, 
LifeTrain’s stakeholders have agreed a set of key 
messages (Box 1) that summarise LifeTrain’s goals. 
To set these messages in context, we need to define 
some terms that have become part of our vocabulary 
during the process of developing LifeTrain, but may 
be unfamiliar or unclear to others.  
Individual professionals have a responsibility to 
manage their own continuing professional develop-
ment (CPD). This is true both for those in regulated 
professions, such as medicine or pharmacy, and those 
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working in unregulated professions, such as scientists 
in academic research or discovery biology. We define 
CPD in accordance with the definition used by the 
Professional Associations Research Network[13] as ‘the 
means by which professionals and scientists in their 
communities maintain, improve and broaden their 
knowledge and skills and develop the personal quali-
ties required in their professional lives’. 
Many regulated professions have their own pro-
cesses for ensuring that their members maintain and 
develop their professional status. These processes 
frequently involve the maintenance of a portfolio of 
CPD that is audited by the relevant professional body. 
This body may award credits for participation in vari-
ous activities, which may include taking formal train-
ing courses, attending conferences, educating or 
training others, and writing and refereeing papers. 
Traditionally, time spent on each activity has been a 
commonly used currency for awarding credits. This 
approach has been called into question[14] because it 
does not provide any evidence that learning has taken 
place or that it has been ‘transformative’, that is, em-
bedded into working practice. Evidence is accumulat-
ing that competency-based approaches to planning and 
recording professional development are more effe-
ctive[15]. Competency is ‘an observable ability of any 
professional, integrating multiple components such as 
knowledge, skills, values and attitudes’. Competencies 
are observable, so their acquisition can be validated 
objectively. Evidence to support competency can be 
collected in a ‘competency portfolio’. 
At the beginning of a professional’s career, new 
competencies are frequently gained through formal 
learning, leading to recognised qualifications. This may 
be supplemented by non-formal learning[16], which 
takes place alongside the mainstream systems of edu-
cation and training and does not typically lead to for-
malised certificates. As an individual progresses thr-
ough his or her career, reliance on formal course- 
based learning decreases, and informal learning[16] 
comes to the forefront. Informal learning is a natural 
accompaniment to everyday life — ‘learning by expe-
rience’. Unlike formal learning, informal learning is 
not necessarily intentional, and so may not be recog-
nised even by individuals themselves as contributing 
to their knowledge and skills. The competency-centric 
approach is attractive to LifeTrain’s stakeholders be-
cause it can be applied to informal and non-formal 
learning, in addition to formal learning.  
Another model, which is helpful for individuals 
using a competency-based approach, is the ‘plan, do, 
review’ cycle (Figure 1). For this, an individual takes 
stock of the competencies that s/he already has, con-
siders which ones she needs to develop, plans how to 
develop them, implements the plan, then records what 
s/he has learnt and reflects on how his or her compe-
tencies have developed before reiterating the cycle. 
 
 
 
Figure 1. The ‘plan, do, review’ cycle. 
 
Training has to keep pace with emerging technolo-
gies for sciences to exploit them fully. For example, 
the widespread adoption of next-generation sequenc-
ing opens up new possibilities in target discovery and 
validation, in the development of personalised medi-
cines, in re-purposing medicines, and in regulatory 
affairs. Biomedical pharmaceutical professionals work-
ing across the entire value chain recognise that they 
need to learn how to take advantage of these oppor-
tunities, but finding appropriate training is notoriously 
difficult. EMTRAIN is addressing this issue by pro-
viding and continuously developing on-course®[17] — 
the resource centre for LifeTrain’s stakeholders. At its 
simplest, on-course® could be described as a pan-Eur-
opean catalogue of courses for postgraduates and 
beyond in the biomedical sciences, which simplifies 
the task of identifying training that already exists. One 
thing that makes on-course® unique is that it incorpo-
rates a set of nine quality standards[18], developed 
jointly by the IMI Education and Training projects and 
supported by LifeTrain’s signatories. Course providers 
who enter their courses in on-course® are encouraged 
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to provide information on which of the quality stan-
dards apply to their courses. This is entirely voluntary, 
but provides added information to course seekers that 
may help them to decide whether or not a particular 
course is appropriate for them. 
In the future, we envisage on-course® providing 
resources that will bring employers and professional 
bodies together to define competency profiles, define 
gaps and work with course providers to fill these. In-
dividuals will be supported to plan their career devel-
opment, maintain a competency portfolio and find 
training to fill skills gaps. Finally, course developers 
and providers will also be supported through guidance 
on learning methods that are especially appropriate for 
adult learners and that support their trainees to trans-
form their learning into their daily working lives. Sup-
port for this approach has recently been strengthened 
by articles addressing the educational and training 
requirements to build 21st-century scientists[19]. 
2.2 Agreed Principles 
LifeTrain’s signatories have developed and agreed to 
four sets of principles, one for each stakeholder group. 
These principles are defined in Box 2. LifeTrain’s 
signatories also agree to the LifeTrain key messages 
and to engage in LifeTrain’s implementation process. 
3. Impact on CPD Programmes in the Bio-
medical Sciences 
LifeTrain has contributed to several international ef-
forts to develop better, more responsive training for 
biomedical professionals and, whilst the core of our 
activities remains funded by the Innovative Medicines 
Initiative and has a European focus, our efforts are 
having an impact beyond Europe. 
For example, LifeTrain's focus on defining compe-
tency requirements for different roles has had a major 
impact on education and training initiatives in com-
putational biology. As a result, the International So-
ciety of Computational Biology (ISCB) published 
competency requirements for bioinformatics profes-
sionals in 2014[20] and is now consulting broadly, 
through a series of interactive workshops, to obtain 
further input to these requirements. The competency 
requirements defined by the ISCB have helped to 
shape several education and training initiatives. In the 
USA, several undergraduate and post-graduate courses 
are being reworked in light of the ISCB competency 
profiles; in Africa the H3BioNet consortium has de-
veloped a pan-African master's course in bioinformat-
ics based on the ISCB competencies, and in Australia 
a bioinformatics engineering course has its learning 
objectives mapped to the ISCB competencies. This 
work has also influenced new CPD programmes for 
clinical bioinformatics in the UK: a newly developed 
competency profile, capturing the clinical bioinfor-
matics competency requirements across a wide range 
of different roles in the UK’s National Health Service, 
is based on the ISCB profile[21]. 
LifeTrain has also influenced the coordination of 
CPD for European pharmacologists, as shown by the 
development and implementation of a new European 
Certified Pharmacologist scheme by EPHAR, the Eu-
ropean Federation of Pharmacological Societies[22].  
In clinical development, LifeTrain's approach has 
been shaped by the development of competency re-
quirements for the specialist in medicines develop-
ment, a new profession embraced by the International 
Federation of Associations of Pharmaceutical Physi-
cians (IFAPP)[1]. A very similar approach is now being 
followed, supported by the imi-train project[23], to de-
velop competency requirements for safety scientists 
working throughout the pharmaceutical value chain — 
from early-stage drug discovery through to post-launch 
pharmacovigilance. Newly funded EU projects (RI-
train, CORBEL and ELIXIR-Excelerate) will develop 
competency profiles for managers and technical spe-
cialists of research infrastructures. 
Implementing these proposed LifeTrain principles 
is still a challenge. The fragmentation of Europe, the 
traditional educational approaches, the lack of compe-
tency profiles in many areas, the lack of experience in 
assessing competency and the existing barriers to 
multidisciplinary training all have to be addressed. 
The above examples clearly demonstrate that such 
changes are possible, however much more still needs 
to be done. A cultural change is required in order to 
implement the education and training changes needed 
to achieve the demands of the European Research Area. 
Another important stepping stone, to help achieve this 
goal, will be the EMBL first open conference on life-
long learning in the biomedical sciences in July 
2016[24]. Inspired by a series of LifeTrain Workshops, 
this is a new international forum to bring together the 
key influencers, policymakers, and stakeholders from 
academia and industry who will shape and implement 
how career-long continuing professional development 
is managed in the future. 
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4. An Open Community with a Unifying Goal 
LifeTrain brings together many excellent, but dispa-
rate, activities into a process towards establishing a 
focused and coherent framework for continuing pro-
fessional development in the biomedical sciences. 
This unique, pan-European collaborative approach pro-
vides the critical mass to achieve a pivotal cultural 
change in Europe’s biomedical, postgraduate re-
searchers’ education and training, and is already in-
fluencing approaches to education and training far 
beyond Europe. It will make a major contribution to 
strengthen the skills and competencies of key profes-
sionals in a rapidly changing environment. In addition, 
it is a clear statement of Europe’s intent to strengthen 
its position in biomedical R&D.  
LifeTrain’s signatories, which include multination-
al pharmaceutical companies, the biotechnological 
sector, European research infrastructures, professional 
and scientific bodies, higher education institutes and 
research institutes, have agreed to the principles of the 
framework (described in the next two sub-sections and 
reproduced with permission[12]) and to continue to 
collaborate to implement LifeTrain. We warmly invite 
others to participate. If you are interested in engaging 
with LifeTrain, Please contact us at 
www.lifetrain.eu/join-us/contact-us/. 
4.1 Key Messages (Box 1) 
Every professional in the biomedical sciences needs to 
develop and maintain an optimal level of professional 
competence in order to contribute to speeding up the 
development of better medicines for patients. 
An individual competency portfolio should capture 
all relevant information in a transparent, easy-to-un-
derstand way in order to facilitate mobility between: 
scientific disciplines; academia, health authorities and 
industry; jobs and countries; and to support career 
development. 
Continuing professional development (CPD) is es-
sential and should be driven by each individual in 
agreement with their employer and in compliance with 
the requirements of the respective professional/scientific 
bodies. 
CPD should be part of a “plan, do, review” cycle 
and can include formal, non-formal and informal 
learning. Each individual should reflect on the learn-
ing and its application in practice. 
Objective assessments of competence should be 
made by the individual and by others, on a regular 
basis throughout the individual’s professional working 
life. 
Needs should be identified and professional train-
ing courses developed and delivered in collaboration 
between industry, technical experts, and course pro-
viders (including universities). They should meet the 
needs of adult-learners and should be available on 
on-course®. 
The ‘plan, do, review’ cycle is shown in Figure 1. 
4.2 Agreed Principles (Box 2) 
Professional/scientific bodies will: 
1. Encourage members to establish and develop 
professional competencies by the provision of a 
framework for lifelong learning and profes-
sional recognition 
2. Support their membership in the development 
and maintenance of a competency portfolio 
3. Recognise the importance of relevant trans-dis-
ciplinary and generic competencies 
4. Recognise core competencies from other IMI 
LifeTrain partner professional/scientific bodies 
5. Work towards the implementation of the IMI 
Education and Training Quality Standard  
6. Recognise continuing education courses that 
fulfil the appropriate IMI Education and Train-
ing Quality Standard as part of an individual’s 
CPD 
7. Recognise the added value of periodic auditing 
of CPD records 
 
Employers will: 
1. Provide input to the development of CPD com-
petency and learning requirements, to ensure 
employer needs are addressed  
2. Recognise the roles and requirements of pro-
fessional/scientific bodies  
3. Recognise the value of competency portfolios 
in career development 
4. Include CPD in individual recruitment and de-
velopment plans  
5. Recognise the value of CPD courses which 
meet the IMI Education and Training Quality 
Standard and recommend them for training  
6. Advise future employees about the importance 
of maintaining professional competence and 
include CPD requirements in job adverts  
7. Recognise the importance of temporary work 
placements for enhancing learning, networking 
and mobility 
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Course providers will: 
1. Develop and deliver professional training cou-
rses in collaboration with industry and other 
employers 
2. Recognise the IMI Education Training Quality 
Standard and, when applicable, meet these 
standards 
3. Address and meet the needs of adult learners. 
Provide flexible, modular/short courses with 
provision of varied learning methodologies  
4. Work with LifeTrain to raise awareness of on- 
course® and, where feasible, enter and update 
data 
 
Individual professionals will: 
1. Develop and maintain an optimal level of pro-
fessional competence in their respective and 
related function(s) in order to contribute to 
speeding up the development of better medi-
cines for patients 
2. Take responsibility for their continuing profes-
sional development 
3. Work closely with employers and professional/ 
scientific bodies to maintain professional com-
petence 
4. Take advantage of the “Plan-Do-Review Cycle” 
new competencies 
5. Develop and maintain a competency portfolio 
and share relevant information with profes-
sional/scientific bodies and employers 
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